Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, ...

Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

On this week's episode of the Business of Biotech, Matt Winton, Ph.D., Chief Commercial and Business Officer at CervoMed, talks about preparing for the late-stage development of neflamapimod in ...

The North Carolina Biotechnology Center leads life sciences economic development for North Carolina by supporting the progression of ideas from research lab to the marketplace. NCBiotech invests in ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion's (OPDP’s) 2026 untitled letters do more than identify a handful of promotional missteps. Read together with the agency’s ...

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

This article was created from the author's presentation at the 2018 Bioprocessing Asia conference, with Cytiva as principal sponsor. The BioProcessing Asia Conference series was created to provide a ...

Canada has unique medical information requirements that demand professionalism, compassion, and local expertise. In this video, Larry Hough, Senior Director of Pharmacovigilance and Medical ...

On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development ...